Education
About Us
Working with TipRanks
Follow Us
Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
APVO Stock Chart & Stats
$0.61
-$0.30(-5.81%)
At close: 4:00 PM EST
$0.61
-$0.30(-5.81%)
Day’s Range― - ―
52-Week Range$6.30 - $1,558.80
Previous CloseN/A
Volume25.11K
Average Volume (3M)11.64M
Market Cap
$7.52M
Enterprise Value$1.41M
Total Cash (Recent Filing)$21.06M
Total Debt (Recent Filing)$3.99M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Apr 01, 2026EPS Estimate
-8.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-40.14
Shares Outstanding997,830
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.05
Enterprise Value/Market Cap0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.86
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Funding RunwayThe $60M standby equity facility materially extends discretionary financing into 2029, reducing immediate liquidity pressure and enabling multi-year clinical development. This structural access to capital supports planned trials and pipeline advancement while preserving strategic flexibility for R&D execution.
Promising RAINIER Trial ResultsStrong safety and remission signals in the RAINIER trial provide clinical validation for mipletamig in frontline AML settings. Durable efficacy and clean safety profile enhance the drug's development pathway, increase the platform's scientific credibility, and materially improve longer-term commercial and partnership prospects if confirmed in later phases.
Leadership ContinuityInternal CEO succession and board expansion emphasize continuity and institutional knowledge retention. Promoting an operator with finance and operational experience reduces execution risk, helps preserve strategic momentum for clinical programs, and supports consistent capital and trial management during the next development phase.
Bears Say
No RevenueThe company reports zero recent revenue, reflecting lack of commercialized products and reliance on clinical success to generate future sales. Absence of top-line cash inflows makes the business structurally dependent on external financing and partnerships for survival and scale, increasing long-term execution risk.
Heavy Cash BurnOperating and free cash flow are deeply negative (~-$26M TTM), indicating persistent cash consumption to fund R&D and operations. Sustained burn necessitates repeated capital raises or licensing deals, which dilute shareholders and constrain strategic optionality if clinical timelines slip or costs rise.
Persistent Operating LossesSubstantial, sustained operating losses and negative returns on equity show profitability is not near-term. Continued negative EBITDA limits reinvestment capacity and increases reliance on external capital; if clinical or regulatory setbacks occur, the company's financial resilience could be quickly strained.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $6.30 and its highest was $1558.80 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $7.52M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Apr 01, 2026 which is in 55 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$40.14 earnings per share for the quarter, missing the consensus estimate of -$37.62 by -$2.52.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Overvalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate is -8.1.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 997,830 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -$40.14 in its last earnings report, missing expectations of -$37.62. Following the earnings report the stock price went up 2.797%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Technical Analysis
Ownership Overview
1.36% Insiders
<0.01% Other Institutional Investors
97.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---